[HTML][HTML] Targeting Toll-like receptors: emerging therapeutics?

EJ Hennessy, AE Parker, LAJ O'neill - Nature reviews Drug discovery, 2010 - nature.com
There is a growing interest in the targeting of Toll-like receptors (TLRs) for the prevention
and treatment of cancer, rheumatoid arthritis, inflammatory bowel disease and systemic …

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

A Barochia, S Solomon, X Cui, C Natanson… - Expert opinion on …, 2011 - Taylor & Francis
Introduction: Sepsis remains a leading cause of death worldwide. Despite years of extensive
research, effective drugs that inhibit the pro-inflammatory effects of lipopolysaccharide (LPS) …

Toll-like receptor modulators: a patent review (2006–2010)

S Basith, B Manavalan, G Lee, SG Kim… - Expert opinion on …, 2011 - Taylor & Francis
Introduction: The immune response is mediated via two parallel immune components, innate
and adaptive, whose effector functions are highly integrated and coordinated for the …

Angiotensin II-induced TLR4 mediated abdominal aortic aneurysm in apolipoprotein E knockout mice is dependent on STAT3

Z Qin, J Bagley, G Sukhova, WE Baur, HJ Park… - Journal of molecular and …, 2015 - Elsevier
Abstract Abdominal Aortic Aneurysm (AAA) is a major cause of mortality and morbidity in
men over 65 years of age. Male apolipoprotein E knockout (ApoE−/−) mice infused with …

Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease?

A Katsargyris, C Klonaris, E Bastounis… - Expert opinion on …, 2008 - Taylor & Francis
Background: Toll-like receptors (TLRs) have been recently recognised as primary receptors
in the innate immune system. Apart from initiating a prompt immune response against …

[HTML][HTML] Truncated Pneumolysin from Streptococcus pneumoniae as a TLR4-Antagonizing New Drug for Chronic Inflammatory Conditions

SF Chang, CN Chen, JC Lin, HE Wang, S Mori, JJ Li… - Cells, 2020 - mdpi.com
Microbial proteins have recently been found to have more benefits in clinical disease
treatment because of their better-developed strategy and properties than traditional …

人Toll 样受体靶向药物研究进展

邢雅玲, 任乐宁, 陈晓娟, 陈忠斌 - 中国生物工程杂志, 2010 - manu60.magtech.com.cn
Toll 样受体(TLR) 是一类模式识别受体, 通过多种信号传递改善免疫系统功能, 活化NF-κB
信号通路, 调节TNF-α, ILs 和IFN-α 等多种细胞因子分泌, 在天然免疫系统中发挥重要作用 …

[图书][B] Eimeria bovis-mediated modulation of the host cell cholesterol metabolism

PH Hamid - 2014 - jlupub.ub.uni-giessen.de
During first merogony E. bovis forms large-sized macromeronts containing> 120,000
merozoites. Given thatobligate intracellular replicating coccidians are generally considered …

[引用][C] 依立托仑的药动学特点和临床应用展望

杨灿, 吕黄伟 - 中国新药与临床杂志, 2010